MBIO: the cash flow

MyFinsight

The latest financial statement is for the year ending 2025-12-31.

Cash Flow	2025-12-31
Net loss	-1,921
Issuance of common shares - equity fee on equity offerings to fortress biotech	395
Common shares issuable - annual stock dividend to fortress biotech	273
Research and development - licenses acquired	0
Stock-based compensation expenses	129
Depreciation expense	34
Amortization of operating lease right-of-use assets	7
Settlement of payables	2,104
Loss on disposal of property and equipment	0
Asset impairment	0
Gain on lease termination	394
Prepaid expenses and other assets	-90
Other receivables	-435
Accounts payable and accrued expenses	-1,971
Payable and accrued expenses - related party	-164
Deferred income	0
Lease liabilities	73
Net cash used in operating activities	-5,264
Proceeds from the sale of property and equipment	1,165
Net cash from investing activities	1,165
Proceeds from issuance of common shares, net of offering costs - equity offering	6,782
Proceeds from issuance of common shares, net of offering costs - at-the-market offering	599
Proceeds from warrant exercises	7,145
Proceeds from issuance of common shares under espp	0
Net cash provided by financing activities	14,526
Net change in cash and cash equivalents	10,427
Cash and cash equivalents, beginning of the period	6,839
Cash and cash equivalents, end of the period	17,266

Unit: Thousand (K) dollars (except for numbers of shares and EPS).